Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1735
Title: Heparanase inhibitors in cancer progression: Recent advances
Authors: Kaur R
Deb P K
Diwan V
Saini B
Keywords: AS1411
Heparanase inhibitors
M402
PG545
PI-88
SST0001
Suramin.
Issue Date: 2021
Publisher: Current Pharmaceutical Design
Abstract: Background: An endo-?-glucuronidase enzyme, Heparanase (HPSE), degrades the side chains of polymeric heparan sulfate (HS), a glycosaminoglycan formed by alternate repetitive units of D-glucosamine and D-glucuronic acid/L-iduronic acid. HS is a major component of the extracellular matrix and basement membranes and has been implicated in processes of the tissue's integrity and functional state. The degradation of HS by HPSE enzyme leads to conditions like inflammation, angiogenesis, and metastasis. An elevated HPSE expression with a poor prognosis and its multiple roles in tumor growth and metastasis has attracted significant interest for its inhibition as a potential anti-neoplastic target.
URI: 10.2174/1381612826666201113105250
http://hdl.handle.net/123456789/1735
Appears in Collections:Journals

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.